Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | CTSH | P09668 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.32 |
| ▸ | GSTM2 | P28161 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | TXNRD1 | Q16881 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30176181 | 1.00 | MAPT (0.35) | MAPTLMNASMN1; SMN2L3MBTL1KDM4E | |
| SCHEMBL20741526 | 0.94 | TSHR (0.34) | MAPTLMNASMN1; SMN2L3MBTL1KDM4E | |
| SCHEMBL16732970 | 0.80 | TSHR (0.41) | MAPTLMNASMN1; SMN2L3MBTL1KDM4E | |
| SCHEMBL13910167 | 0.78 | SMN1; SMN2 (0.35) | MAPTLMNASMN1; SMN2L3MBTL1KDM4E | |
| SCHEMBL25336107 | 0.77 | NPC1 (0.33) | SMN1; SMN2TSHRALDH1A1HTTPOLB | |
| SCHEMBL20580580 | 0.77 | SSTR4 (0.38) | MAPTLMNASMN1; SMN2KDM4ESYK | |
| SCHEMBL20741559 | 0.77 | SYK (0.37) | SYK | |
| SCHEMBL30176186 | 0.77 | SYK (0.37) | SYK | |
| SCHEMBL29989013 | 0.77 | SYK (0.37) | SYK | |
| SCHEMBL16084452 | 0.77 | HCAR3 (0.39) | L3MBTL1SYKNPSR1TXNRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11555026-B2 | AHR inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2023-01-17 | — | — | US | disclosed |
| US-20210017153-A1 | AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2021-01-21 | — | — | US | disclosed |
| US-10696650-B2 | AHR inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2020-06-30 | — | — | US | disclosed |
| EP-3668496-A1 | AHR INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2020-06-24 | — | — | EP | disclosed |
| WO-2019036657-A1 | AHR INHIBITORS AND USES THEREOF | KYN THERAPEUTICS (US) | 2019-02-21 | — | — | WO | disclosed |
| US-20190055218-A1 | AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2019-02-21 | — | — | US | disclosed |
| US-9758480-B2 | 1-(cycloalkyl-carbonyl)proline derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-09-12 | — | — | US | disclosed |
| US-20150210640-A1 | 1-(CYCLOALKYL-CARBONYL)PROLINE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2015-07-30 | — | — | US | disclosed |
| US-20090098189-A1 | AZAINDOLES AS INHIBITORS OF SOLUBLE ADENYLATE CYCLASE | BAYER SCHERING PHARMA AG (DE) | 2009-04-16 | — | — | US | disclosed |
| US-20090098189-A1 | AZAINDOLES AS INHIBITORS OF SOLUBLE ADENYLATE CYCLASE | BAYER SCHERING PHARMA AG (DE) | 2009-04-16 | — | — | US | disclosed |
| US-20090098189-A1 | AZAINDOLES AS INHIBITORS OF SOLUBLE ADENYLATE CYCLASE | BAYER SCHERING PHARMA AG (DE) | 2009-04-16 | — | — | US | disclosed |
| EP-2036906-A1 | Azaindoles as inhibitors of soluble adenylate cyclase | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-03-18 | — | — | EP | disclosed |
| WO-2009030725-A2 | AZAINDOLES AS INHIBITORS OF SOLUBLE ADENYLATE CYCLASE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-03-12 | — | — | WO | disclosed |
| WO-2009030725-A2 | AZAINDOLES AS INHIBITORS OF SOLUBLE ADENYLATE CYCLASE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11555026-B2 | AHR inhibitors and uses thereof | AHR, ARNT, AIPL1 | MAPT 4714/4885LMNA 4108/4885SMN1; SMN2 4882/4885 |
| US-20210017153-A1 | AHR INHIBITORS AND USES THEREOF | AHR, ARNT, AIPL1 | MAPT 4714/4885LMNA 4108/4885SMN1; SMN2 4882/4885 |
| US-20090098189-A1 | AZAINDOLES AS INHIBITORS OF SOLUBLE ADENYLATE CYCLASE | ADCY1, ADCY5, ADCY2 | MAPT 4758/4885LMNA 4108/4885SMN1; SMN2 4433/4885 |
| US-10696650-B2 | AHR inhibitors and uses thereof | AHR, ARNT, AIPL1 | MAPT 4714/4885LMNA 4108/4885SMN1; SMN2 4882/4885 |
| US-20190055218-A1 | AHR INHIBITORS AND USES THEREOF | AHR, ARNT, AIPL1 | MAPT 4714/4885LMNA 4108/4885SMN1; SMN2 4882/4885 |
| US-20150210640-A1 | 1-(CYCLOALKYL-CARBONYL)PROLINE DERIVATIVE | RB1, F2, SFPQ | MAPT 4798/4885LMNA 2666/4885SMN1; SMN2 3586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.